摘要
目的观察沙利度胺对癌性恶病质小鼠恶病质状态的影响,探讨沙利度胺治疗癌性恶病质的作用机制。方法建立C57小鼠癌性恶病质模型,观察沙利度胺对恶病质小鼠的一般状况,如体重、摄食量、饮水量的影响,观察与肿瘤坏死因子-α(TNF-α),白细胞介素-6(IL-6)的水平变化。结果沙利度胺能明显增加癌性恶病质小鼠摄食量及饮水量,抑制体重下降(P<0.05),可显著降低TNF-α和IL-6的水平(P<0.05),与甲羟孕酮相比无显著性差异。结论沙利度胺通过降低血清TNF-α和IL-6的水平来改善癌性恶病质症状,调节代谢紊乱。
Objective To obearve the efficacy of thalidomide in the treatment of cancer cachexia （CC） and study the machanism of thalidomide on cancer cachexia mice. Methods The animal CC model was developed by inoculating mice C57 with tumor Lewis lung adenocarcinoma. Observations were made on the changes of physiological conditions （body weight, food and water intake） , the serum levels of tumor necrosis factor-α（TNF-α）, interleukin-6 （IL-6） were observed. Results Thalidomide could significantly increase water and food intake of CC mice, and significantly inhibit the loss of body weight （P 0.05）. Levels of TNF-α and IL-6 were significantly decreased in the thalidomide group （P 0.05）. There was no significant difference between the thalidomide group and the Medroxyprogesterone （MPA） group. Conclusions Thalidomide may potentially moderate cancer cachexia state, adjust metabolic disorder through down-regulating the serum levels of TNF-α and IL-6.
出处
《北京医学》
CAS
2010年第7期559-561,共3页
Beijing Medical Journal
